

Oncology Annual Review Summary

Date: October 15, 2023

Patient: Williams, Helen Grace **ID:** SYN184 **DOB:** January 18, 1949 (74 F)

Provider: Benjamin Carter, MD

Subject: Annual Oncology Review - Stage IV ALK+ NSCLC Stable on Alectinib

Summary of Status: Ms. Williams is a 74 y/o F diagnosed 02/19/2021 with Stage IV Lung Adenocarcinoma metastatic to bone (spine, ribs, pelvis). Pathology confirmed Adenocarcinoma with **signet ring cell features** (~30% of tumor), TTF-1+. Molecular testing identified an **EML4-ALK fusion (variant 1)**. PD-L1 was high (**TPS 60%**, though not relevant for initial Tx). She started first-line **Alectinib 600mg BID on 03/12/2021** and has been on continuous therapy for approximately **31 months**.

Clinical Course & Current Status:

- **Response:** Achieved excellent partial response within 3-6 months, with resolution of presenting bone pain and marked sclerosis/decreased avidity of bone lesions. Has maintained stable PR since.
- **Tolerance:** Tolerated Alectinib remarkably well long-term. Reports only mild chronic toxicities:
 - Grade 1 Myalgia: Occasional mild aches, non-limiting. CPK levels consistently WNL.
 - Grade 1 Peripheral Edema: Mild bilateral ankle edema, controlled well with compression stockings PRN, no diuretics needed.
 - Grade 1 Dry Skin: Uses moisturizer.
 - No significant fatigue, constipation, LFT abnormalities, ILD, visual issues, or bradycardia.
- **Current Symptoms:** Asymptomatic from cancer. ECOG 0. Maintains active lifestyle (travels, volunteers).

Objective Data:

- **Exam:** Unremarkable today. Mild trace ankle edema.
- **Labs (10/10/23):** CBC/CMP/LFTs/CPK all WNL.
- **Imaging (CT C/A/P + Bone Scan + Brain MRI, Sept 28, 2023):** Stable partial response systemically (minimal residual lung primary scar, stable sclerotic bone mets). Brain MRI remains negative. No change from scans 6 months prior.

Assessment: Excellent, durable ongoing partial response to Alectinib after >2.5 years. Minimal toxicity. ALK+ NSCLC well controlled.

Plan:

1. **Continue Alectinib 600mg BID.**
2. **Continue Zoledronic Acid 4mg IV q6 months** for bone health (last dose Aug 2023). Continue Ca/D.
3. Monitoring: Labs q6 mos, Imaging (CT C/A/P + Brain MRI) q6 mos.
4. F/U: Clinic visit (telehealth optional) in 6 mos post-scans. RTC sooner PRN.

(Signed electronically) B. Carter, MD

